|
|
Article: Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: August 1999.(Brief Article)
- Article from:
- Bioworld Financial Watch
- Article date:
- September 27, 1999
CopyrightCOPYRIGHT 1999 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Non-U.S. Clinical Trials, Regulatory Submissions,
Recommendations And Approvals: August 1999
Company Product Description Indication
CANCER
Biomira Inc.BLP25 Synthetic 25-amino acid Advanced non-small
(Canada)vaccine sequence of the MUC-1 cell lung cancer
cancer mucin, encapsulated
in a synthetic liposomal
delivery system, designed
to induce an immune response
to cancer cells
British Biotech Marimastat Oral matrix metalloproteinase Gastric ...
Related newspaper, magazine, and journal articles:
|
|
Article: XES Changes EPS Estimate of CANGENE CORP.
TFN/Nelson's Research Reports;
October 22, 2008 ;
344 words
...Oct 22, 2008 (Nelson's Broker Summaries via COMTEX) -- Company: CANGENE CORP Report Headline: "Cangene's Q4/F08 beats forecasts" Report Date: October 20, 2008 Current FY EPS Estimate [FY2009 ...
|
|